Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans.

PloS One
Liesbeth LenaertsLieve Naesens

Abstract

Application of human adenovirus type 5 (Ad5) derived vectors for cancer gene therapy has been limited by the poor cell surface expression, on some tumor cell types, of the primary Ad5 receptor, the coxsackie-adenovirus-receptor (CAR), as well as the accumulation of Ad5 in the liver following interaction with blood coagulation factor X (FX) and subsequent tethering of the FX-Ad5 complex to heparan sulfate proteoglycan (HSPG) on liver cells. As an alternative vector, mouse adenovirus type 1 (MAV-1) is particularly attractive, since this non-human adenovirus displays pronounced endothelial cell tropism and does not use CAR as a cellular attachment receptor. We here demonstrate that MAV-1 uses cell surface heparan sulfate proteoglycans (HSPGs) as primary cellular attachment receptor. Direct binding of MAV-1 to heparan sulfate-coated plates proved to be markedly more efficient compared to that of Ad5. Experiments with modified heparins revealed that the interaction of MAV-1 to HSPGs depends on their N-sulfation and, to a lesser extent, 6-O-sulfation rate. Whereas the interaction between Ad5 and HSPGs was enhanced by FX, this was not the case for MAV-1. A slot blot assay demonstrated the ability of MAV-1 to directly interact with FX,...Continue Reading

References

May 23, 2001·Trends in Cardiovascular Medicine·A R Rezaie
May 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Theodore SmithSusan C Stevenson
May 29, 2004·The Journal of Biological Chemistry·Keiji NogamiPhilip J Fay
Aug 3, 2005·Nature Reviews. Cancer·Mark M Fuster, Jeffrey D Esko
Mar 25, 2006·Future Oncology·Daniel T ReinDavid T Curiel
Sep 21, 2006·Molecular Cancer Therapeutics·George W YipMartin Götte
Sep 22, 2006·Journal of Virology·Jiansong XieSarah F Hamm-Alvarez
Jan 25, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Angelika B KritzAndrew H Baker
Apr 27, 2007·Nature·Joseph R BishopJeffrey D Esko
May 2, 2007·The Journal of Cell Biology·Mark M FusterJeffrey D Esko
Sep 15, 2007·Journal of Virology·Nelson C Di PaoloDmitry M Shayakhmetov
Nov 29, 2007·Protein Science : a Publication of the Protein Society·Robson Q MonteiroIvo M B Francischetti
Feb 13, 2008·Cell·Simon N WaddingtonAndrew H Baker
Apr 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·O KalyuzhniyD M Shayakhmetov
May 29, 2008·Genome Biology·Jorge FilmusJonathan Rast
Oct 8, 2008·Annals of Biomedical Engineering·Kimberly Forsten-WilliamsMatthew A Nugent
Dec 10, 2008·The Journal of Gene Medicine·Liesbeth LenaertsLieve Naesens
Jan 30, 2009·Journal of Virology·Sharmila RamanKatherine R Spindler
Sep 29, 2009·Current Opinion in Chemical Biology·Tatiana N LaremoreRobert J Linhardt
May 21, 2011·The Journal of Biological Chemistry·Anne K ZaissHarvey R Herschman
Jun 22, 2011·Cold Spring Harbor Perspectives in Biology·Stephane SarrazinJeffrey D Esko

❮ Previous
Next ❯

Citations

Jan 25, 2013·Therapeutic Delivery·Lali K Medina-Kauwe
Feb 7, 2014·Human Gene Therapy·Estrella Lopez-GordoRamon Alemany
Oct 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ha T HuynhWilliam S Sly
Oct 20, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Julio Alonso-PadillaAndrew H Baker
Oct 23, 2012·Cellular Microbiology·Nina Wolfrum, Urs F Greber
Nov 21, 2019·Cell Reports·Gloria P LarsonAndrew Mehle

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
flow cytometry
biosensor
chip
surface plasmon resonance
FCS
ELISA

Software Mentioned

Cell Quest
COMPARE

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.